Quarterly report · Q3
2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.18T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.05T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥29.9bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥20.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥31.2bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥30.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥14.9bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.50T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.44T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.04T | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥464.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥200.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥107.92 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.22 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.24 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥290m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.94T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.92T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥14.0bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥25.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥40.0bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥28.2bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥11.7bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥484m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥200.4bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥200.0bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥395m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥2.18T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥372m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.82T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.81T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥16.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥25.8bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥992m |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥186.8bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥186.3bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥429m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥2.07T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥2.05T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥24.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥19.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 381
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment loss el | CurrentYTDDuration | 257000000 | JPY |
| Loss on valuation of investment securities el | Prior1YTDDuration | 933000000 | JPY |
| Loss on valuation of investment securities el | CurrentYTDDuration | 13000000 | JPY |
| Provision for loss on anti monopoly act el | Prior1YTDDuration | 993000000 | JPY |
| Provision for loss on anti monopoly act el | CurrentYTDDuration | － | JPY |
| Other el | Prior1YTDDuration | 79000000 | JPY |
| Other el | CurrentYTDDuration | － | JPY |
| Extraordinary loss | Prior1YTDDuration | 2102000000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 505000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 22683000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 30909000000 | JPY |
| Income taxes current | Prior1YTDDuration | 7088000000 | JPY |
| Income taxes current | CurrentYTDDuration | 7838000000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 731000000 | JPY |
| Income taxes deferred | CurrentYTDDuration | 2140000000 | JPY |
| Income taxes | Prior1YTDDuration | 7819000000 | JPY |
| Income taxes | CurrentYTDDuration | 9979000000 | JPY |
| Profit loss | Prior1YTDDuration | 14863000000 | JPY |
| Profit loss | CurrentYTDDuration | 20930000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 14822000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 20871000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 41000000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 58000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 6593000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 2736000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | -0 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | -2000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 146000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 115000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | -417000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -318000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 6322000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 2531000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 21186000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 23461000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 21144000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 23402000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 41000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 58000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1808614000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 186350000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 25841000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 27128000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2047935000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 2047935000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 13137000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 429000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 10568000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |